Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on News Break! Middle East.
Press releases published on August 5, 2025
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
GlobeNewswire
·
August 5, 2025
IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), …
CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production
GlobeNewswire
·
August 5, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness …
Fasoo Strengthens Critical IP & CAD File Protection in Energy Sector with Enterprise DRM & Secure Collaboration Platform
EIN Presswire
·
August 5, 2025
SEOUL, SOUTH KOREA, August 5, 2025 /EINPresswire.com/ -- — Fasoo, the leader in data-centric security, today announced its growing adoption across the energy sector, as companies turn to its Enterprise DRM and secure collaboration platform. These …
Entrée Resources Provides Corporate Update
GlobeNewswire
·
August 5, 2025
VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) provides an update regarding efforts to transfer the Shivee Tolgoi and Javkhlant mining licenses (the “JV Licenses”) in …
Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project
GlobeNewswire
·
August 5, 2025
VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that field crews are mobilizing to the Robinsons River Salt Project in Newfoundland to …
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
August 5, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend …
InspireMD Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
--- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced …
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire
·
August 5, 2025
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech …
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints On track to share pivotal trial results from PEAK …
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
GlobeNewswire
·
August 5, 2025
All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well tolerated Company expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this year Lack of approved norovirus treatments or vaccines …
American Tungsten Strengthens Leadership Team to Drive Mining Operations Expansion
GlobeNewswire
·
August 5, 2025
Vancouver, BC, Aug. 05, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) is pleased to announce the appointment of David Sabourin (PE, MBA) as Vice President of Mining Operations and …
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 5, 2025
- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company …
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
GlobeNewswire
·
August 5, 2025
GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune …
Neuronetics Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 5, 2025
Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $ …
Envision Pharma Group appoints Tom Langan as Chief Executive Officer
GlobeNewswire
·
August 5, 2025
Envision Pharma Group appoints Tom Langan as Chief Executive Officer Leading industry executive with 30 years’ of experience providing technology-enabled solutions to life sciences companies Fairfield, Connecticut, USA, and Horsham, United Kingdom - August …
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
GlobeNewswire
·
August 5, 2025
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination …
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
August 5, 2025
– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, …
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
GlobeNewswire
·
August 5, 2025
$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand $55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and Ligand Proceeds extend …
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 5, 2025
BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of …
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 5, 2025
Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to …